Ginkgo Bioworks Holdings Inc vs Comfort Systems USA Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.94 (market cap $590.53M), while Comfort Systems USA Inc trades at $1,687.01 (market cap $62.49B). The key difference: Comfort Systems USA Inc is far larger — about 105.8× Ginkgo Bioworks Holdings Inc's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | FIX | |
|---|---|---|
Market Cap | $590.53M | $62.49B |
Sector | Health | Technology |
52-Week High | $16.14 | $2.07K |
52-Week Low | $5.48 | $532.14 |
Enterprise Value | $627.78M | $61.78B |
Dividend Yield | — | 0.15% |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Comfort Systems USA (FIX) trades at $1,732.03, down 1.37% on the day, amid a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations with Q1 2026 EPS of $10.51 versus $6.81 expected, driven by robust revenue growth and a 12.07% net income margin. Recent news highlights the company's expansion in modular capabilities and leadership in AI infrastructure demand, with a record backlog supporting future growth.
The stock presents a compelling growth story with strong earnings momentum and analyst consensus pointing to significant upside (price target $2,100), but faces risks from execution challenges on its record backlog and premium valuation multiples (P/E 51.24). Investors should weigh the company's solid cash flow generation and market position against technical weakness and high expectations.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →